FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Investing.com -- Shares in Swiss biotechnology firm Bachem Holding (SIX:BANB) shot up nearly 27% Thursday after the company raised its full-year (FY25) guidance following a strong performance in the first half of 2025 (1H25).
The company’s revenue rose 34.1% in local currency to CHF 313 million. According to UBS, the figure beat the consensus estimate of CHF 264 million.
EBITDA came in at CHF 91 million, 49% ahead of the CHF 61 million consensus, with margins improving by 600 basis points year-over-year to 29.1%.
Net income climbed 39% to CHF 50 million, also exceeding expectations, UBS said.
Growth was led by the Commercial API segment, where sales jumped 32.4% to CHF 168 million, supported by improved facility utilization.
CMC Development revenue grew nearly 37% to CHF 123.7 million, reflecting robust demand for peptide and oligonucleotide projects.
Research & Specialties declined 8.5% to CHF 20.8 million.
Bachem raised its full-year 2025 sales guidance to 13–18% growth in local currency, up from the previous 10–15% range, and reaffirmed its target for an EBITDA margin in the high twenties.
"Assuming a continued FX headwind, at mid-point we estimate guidance implies CHF681m sales (vs cons CHF678m) and an EBITDA of CHF177m (vs cons CHF193m)," UBS analyst Tanya Hansalik said in a note.
For 2026, the company continues to project sales above CHF 1 billion and EBITDA margin exceeding 30%, contingent on the ramp-up of its new Building K production facility.
"Bachem delivering a better than expected 1H25 and upgraded guidance should prove reassuring for investors for FY26 targets," the analysts continued. "Though FY25 we don’t see revision upside as consensus is already at the upper end of guidance, we expect a positive share price reaction today."